Literature DB >> 16125032

Subcutaneous administration of cefepime.

Paul Walker1, Melinda N Neuhauser, Vincent H Tam, Jie S Willey, J Lynn Palmer, Eduardo Bruera, Randall A Prince.   

Abstract

Management of symptomatic infections can aid in palliation. We investigated the pharmacokinetics and tolerability of cefepime given as a subcutaneous infusion. This novel route of administration is proposed as an alternative to intravenous and intramuscular administration for patients treated outside an institutional setting, such as home hospice. Ten healthy adult volunteers received a single dose of 1g cefepime infused subcutaneously over 30 minutes. Serial serum samples (0.5, 1, 1.5, 2, 4, 6, 9, and 12 hours) were obtained after the end of infusion, and cefepime concentrations were determined by high performance liquid chromatography (HPLC). All serum concentration profiles were modeled by a population pharmacokinetic analysis using the Non-Parametric Adaptive Grid (NPAG) program. Acceptability of administration was evaluated using subjective sensation grading, observation of the subcutaneous site, and a final global evaluation. The mean (median) Cmax, beta-t1/2, AUC0-oo and total clearance were found to be 36.1 (30.9) mg/L, 2.34 (2.56) hours, 134.8 (125.3) h*mg/L, and 7.42 (7.98) L/h, respectively. All infusions were completed without difficulty or discomfort. No drug side effects occurred. The global acceptability was "strongly agreeable" with all the subjects. Subcutaneous infusion of cefepime appeared to result in a pharmacokinetic profile similar to that of an intramuscular injection. Our evaluations showed excellent tolerability and acceptability. These favorable results warrant further clinical evaluation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16125032     DOI: 10.1016/j.jpainsymman.2005.03.007

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  4 in total

1.  Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model.

Authors:  Vincent H Tam; Daniel N Cohen; Kimberly R Ledesma; Bobby Guillory; Katrina Chan; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  The Tipper-Strominger Hypothesis and Triggering of Allostery in Penicillin-Binding Protein 2a of Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Jennifer Fishovitz; Negin Taghizadeh; Jed F Fisher; Mayland Chang; Shahriar Mobashery
Journal:  J Am Chem Soc       Date:  2015-05-18       Impact factor: 15.419

Review 3.  Clinical Pharmacokinetics and Pharmacodynamics of Cefepime.

Authors:  Gwendolyn M Pais; Jack Chang; Erin F Barreto; Gideon Stitt; Kevin J Downes; Mohammad H Alshaer; Emily Lesnicki; Vaidehi Panchal; Maria Bruzzone; Argyle V Bumanglag; Sara N Burke; Marc H Scheetz
Journal:  Clin Pharmacokinet       Date:  2022-06-29       Impact factor: 5.577

4.  Prevention of Surgical Site Infections and Biofilms: Pharmacokinetics of Subcutaneous Cefazolin and Metronidazole in a Tumescent Lidocaine Solution.

Authors:  Jeffrey A Klein; Loralie J Langman
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-05-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.